Cleared Traditional

Simplexa COVID-19 Direct

K212147 · Diasorin Molecular, LLC · Microbiology

Sep 2022

Decision

431d

Days

Class 2

Risk

About This 510(k) Submission

K212147 is an FDA 510(k) clearance for the Simplexa COVID-19 Direct, a Respiratory Specimen Nucleic Acid Sars-cov-2 Test (Class II — Special Controls, product code QQX), submitted by Diasorin Molecular, LLC (Cypress, US). The FDA issued a Cleared decision on September 13, 2022, 431 days after receiving the submission on July 9, 2021. This device falls under the Microbiology review panel. Regulated under 21 CFR 866.3981.

Submission Details

510(k) Number	K212147 FDA.gov
FDA Decision	Cleared SESE
Date Received	July 09, 2021
Decision Date	September 13, 2022
Days to Decision	431 days
Submission Type	Traditional
Review Panel	Microbiology (MI)
Summary	Summary PDF

Device Classification

Product Code	QQX — Respiratory Specimen Nucleic Acid Sars-cov-2 Test
Device Class	Class II — Special Controls
CFR Regulation	21 CFR 866.3981
Definition	A Device To Detect And Identify Nucleic Acid Targets In Respiratory Specimens From Sars-cov-2 That Cause Covid-19 Is An In Vitro Diagnostic Device Intended For The Detection And Identification Of Sars-cov-2 Nucleic Acid Targets In Human Clinical Respiratory Specimens From Patients Suspected Of Covid-19 Based On Signs And Symptoms Of Respiratory Infections By Their Healthcare Providers. The Device Is Intended To Aid In The Diagnosis Of Covid-19 In Conjunction With Other Clinical, Epidemiologic, And Laboratory Data Or Other Risk Factors.